These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27322177)

  • 1. Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen.
    Mazor Y; Yang C; Borrok MJ; Ayriss J; Aherne K; Wu H; Dall'Acqua WF
    PLoS One; 2016; 11(6):e0157788. PubMed ID: 27322177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
    Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
    MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
    Tang Y; Lou J; Alpaugh RK; Robinson MK; Marks JD; Weiner LM
    J Immunol; 2007 Sep; 179(5):2815-23. PubMed ID: 17709495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
    J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors.
    Cai Z; Fu T; Nagai Y; Lam L; Yee M; Zhu Z; Zhang H
    Cancer Res; 2013 Apr; 73(8):2619-27. PubMed ID: 23396586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered antibody Fc variants with enhanced effector function.
    Lazar GA; Dang W; Karki S; Vafa O; Peng JS; Hyun L; Chan C; Chung HS; Eivazi A; Yoder SC; Vielmetter J; Carmichael DF; Hayes RJ; Dahiyat BI
    Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4005-10. PubMed ID: 16537476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.
    Mohseni Nodehi S; Repp R; Kellner C; Bräutigam J; Staudinger M; Schub N; Peipp M; Gramatzki M; Humpe A
    PLoS One; 2012; 7(8):e42426. PubMed ID: 22879978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance.
    Jo M; Kwon HS; Lee KH; Lee JC; Jung ST
    MAbs; 2018; 10(2):278-289. PubMed ID: 29173039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural mechanism of high affinity FcγRI recognition of immunoglobulin G.
    Lu J; Sun PD
    Immunol Rev; 2015 Nov; 268(1):192-200. PubMed ID: 26497521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J; Jiang L; Pan LZ; LaBarre MJ; Anderson D; Reff M
    Biotechnol Bioeng; 2001 Aug; 74(4):288-94. PubMed ID: 11410853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors.
    Hintersteiner B; Lingg N; Zhang P; Woen S; Hoi KM; Stranner S; Wiederkum S; Mutschlechner O; Schuster M; Loibner H; Jungbauer A
    MAbs; 2016; 8(8):1548-1560. PubMed ID: 27559765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.